Recently, Professor He Le Ye, the chief of Urology Department of our hospital, successfully completed four cases of Ar-He knife cryoablation for prostate cancer, after which all patients achieved satisfactory results and were discharged from the hospital. The Department of Urology was the first to carry out this new technology in China in 2009, and is still the only clinical department in Hunan Province to carry out this technology, which is at the leading level in China. This time, the latest American third generation argon helium knife freezing equipment is used, which is safer and more effective. According to the introduction, prostate cancer is a common malignant tumor among men in Europe and the United States, with the second highest mortality rate. With the improvement of living standard, the incidence rate in China is also increasing year by year. The urology department has seen a 45% increase in the number of new prostate cancer patients in 2013 compared to 2010. To date, the Department of Urology has treated nearly 452 cases of prostate cancer patients, ranking first in the province. The early stage of prostate cancer treatment is mainly based on surgical radical treatment, while about 70% of patients admitted to urology are already in advanced stage, losing the chance of radical treatment and having poor prognosis. How to reduce the tumor load as much as possible, prolong the survival time of patients and improve the quality of life is the difficulty and hot spot in the treatment of advanced prostate cancer. Surgery is performed by placing multiple probes from the perineum into the prostate tumor lesion under the guidance of transrectal ultrasound. The rapid freezing of argon gas causes the entire prostate tumor to be encased in an “ice ball” and the temperature in the gland to reach -140°C. The high-pressure helium gas expands rapidly inside the tip of the knife, rapidly heating the frozen lesion and causing it to burst and rapidly warm up to strike the lesion again. This causes the local tumor tissue, cells and blood vessels to disintegrate and necrosis. In addition, some immune factors can be produced to promote the apoptosis of tumor cells. Patients can get out of bed one day after surgery and can be discharged in 3~5 days. Argon-helium cryotherapy for tumors is increasingly recognized internationally for its safety and effectiveness, precise ablation, targeted minimally invasive, and real-time monitoring. Argon-helium cryotherapy for prostate cancer can achieve the treatment effect of surgical procedure without surgery, with less trauma, less bleeding, less complications and faster recovery, which is conducive to improving the quality of life of patients.